Hims & Hers Health, Inc. (NYSE:HIMS) has been under pressure this week, with shares declining over 10%, following Eli Lilly's (NYSE:LLY) recent earnings report. Eli Lilly reported a significant miss in GLP-1 revenue, attributing it to stock shortages and increased competition from compounders. This development has raised concerns about the sustainability of compounded GLP-1 medications, which are a part of Hims' product offerings.
Earnings Preview for Hims
Looking ahead to its upcoming earnings report, Hims is expected to present its results next week, with analysts watching closely for signs of demand resilience across its telehealth and wellness offerings. The Street projects revenue of approximately $382 million for the quarter, which represents a 69% growth year-over-year, reflecting solid growth as Hims continues to expand its customer base and offerings. Management has guided for adjusted EBITDA with a midpoint of $38 million, and analysts anticipate a slight profit of around $0.04 per share, an improvement over the same period last year, which reported a loss of $0.04 per share, as the company edges closer to profitability.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。